Global Biopsy Devices Market Size, Share, Trends, COVID-19 impact and Growth Analysis Report – Segmented By Type, Product, Application, End-User and Region – Industry Forecast (2024 to 2029)

Updated On: January, 2024
ID: 1607
Pages: 175

Biopsy Devices Market Size (2023 to 2028)

As per our research report, the global biopsy devices market size is estimated to be worth USD 3178 million by 2028 and USD 2217 million in 2023, growing at a CAGR of 7.47% during the forecast period.

A biopsy is a procedure to perform surgical removal of tissue from an organ to determine the presence or extent of disease, generally cancer or inflammatory conditions, typically performed by surgeons, radiologists, and interventional cardiologists. Biopsies can be performed on any organ using a specific biopsy device to confirm for cancer or celiac diseases. The usage of biopsy devices varies according to the type of organ under consideration. Conventional biopsy devices can be used along with advanced imaging technologies such as MRI Guided biopsy, stereotactic guided biopsy, ultrasound-guided biopsy, CT scan, etc.

Biopsy devices help perform integrated procedures that are important to perform biopsies in critical areas of the body, such as the lungs, liver, and kidney. A biopsy is the surgical removal of tissue from an organ to determine the presence or level mostly cancerous and inflammatory conditions. This diagnostic process is usually performed by surgeons, radiologists, and interventional cardiologists, to substantiate the presence of cancerous tissue.


Y-O-Y growth in cancer incidence, growing demand for minor invasive surgeries, and increasing support and initiatives from the governments are primarily accelerating the development of the global biopsy devices market.

The global biopsy devices market is further expected to be driven by rising incidences of chronic medical conditions, a fast-growing senior population, rising healthcare expenditures, and considerable research and development (R&D) efforts during the forecast period. In addition, consumer awareness of the availability of diagnostic and screening procedures for chronic diseases is increasing, which is driving demand for integrated technologies such as stereotactic-guided biopsies and smart biopsy systems that help distinguish healthy cells from tumorous cells, which is also expected to accelerate the growth rate of the global biopsy devices market.

Additionally, increased public awareness of the need for early disease detection and improved product designs are also driving the growth of the global biopsy devices market. Although the research in biopsy diagnostics is not as advanced as in Western countries, regions such as Asia-Pacific are still growing faster than their western counterparts. Hence, more funding is being received for cancer diagnostic research.


High prices of these cutting-edge instruments are a deterrent in price-sensitive markets such as South East Asia. In addition, product recalls due to a rising number of quality and accuracy issues have hindered the growth of this market. Recently, the Asia-Pacific region has been witnessing a massive challenge in the growing COVID-19 cases, which has adversely influenced even cancer diagnostics. As a result, cancer patients are faced with tremendous diagnosis and treatment issues, and progress tests are delayed as hospitals struggle with rising COVID-19 cases.

Lack of or poor awareness of the diagnosis of chronic diseases is a major restraint for the market. Additionally, factors such as time-consuming, irreproducible nature, qualification needs, and required standardizations are hindering the market's growth rate.

Impact of COVID-19 on the global biopsy devices market:

COVID 19 has been declared a pandemic by the World Health Organization (WHO). The coronavirus has spread to every corner of the globe, wreaking havoc on various industries, including healthcare. The cancer diagnostics industry has been hit the worst. Increased COVID 19 cases pose a significant concern in regions such as North America, Europe, and Asia-Pacific. According to the WHO, 19 countries have been afflicted by COVID, and outbreak trends are being managed steadily. According to an April 2020 article, cancer patients in India experience significant difficulties as treatments and diagnoses are canceled, postponed, or rescheduled. The healthcare workers were constantly occupied with administering and managing the growing number of COVID-19 cases. The gadget production process was halted during the first half of the pandemic, i.e., during the lockdown, to prevent the virus from spreading widely. The medical personnel is the frontline fighters in the fight against COVID 19 to safeguard the safety of the patients. Despite being in decline mode for more than four months, the biopsy devices have begun to heal following the uplift of lockdown.




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Covered

By Product, Type, Application, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa


This research report on the global biopsy devices market has been segmented & sub-segmented based on the product, type, application, end-user, and region.

Biopsy Devices Market - By Product:

  • Instruments
    • Manual
    • Automated
    • Semi-automated
  • Consumables
    • Reagents
    • Kits

Biopsy Devices Market – By Type:

  • Needle Biopsy
    • core needle biopsy
    • fine-needle biopsy
    • vacuum-assisted biopsy
  • Surgical Biopsy
    • Incisional biopsy
    • Excisional biopsy

The needle biopsy segment is forecasted to hold the largest share in the global market during the forecast period based on the type. Factors such as the growing number of breast cancers, gastrointestinal tract diseases, and soft tissue sarcomas are accelerating this segment. According to the National Cancer Institute (NCI), in 2019, around 61,780 leukemia cases and 22,480 people died due to leukemia in the U.S in 2019.

The vacuum-assisted biopsy sub-segment was the top-performing under needle biopsy segment in 2019. The vacuum-assisted biopsy device is one of the most important diagnostic procedures. The increasing demand for vacuum-assisted biopsy devices, ongoing research, and development in the medical devices sector has led to the launch of new equipment and systems worldwide. The mentioned above factors propel the biopsy devices market globally.

Biopsy Devices Market – By Application:

  • Scientific Research
  • Medical Diagnosis
  • Agricultural Applications
  • Genetic Fingerprinting
  • Sex Determination

Biopsy Devices Market – By End User:

  • Pharmaceutical and Biology Industry
  • Academic Research Institute
  • Contract Research Organizations
  • Forensic Labs

Biopsy Devices Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

North America holds the most significant share in the global biopsy device market due to the increasing geriatric population. Europe has the second primary market for biopsy devices due to the acceptance of advanced technology in biotechnology and research and innovation technologies. The Asia Pacific is estimated to represent strong potential market growth in the biopsy devices market due to fast technological advancements. As a result, the Asia-Pacific region is expected to witness the highest CAGR during the forecast period. The rapid growth of this segment can be attributed to the rising prevalence of cancer moreover large populations in countries such as China and India, improving healthcare infrastructure. However, patient safety risks associated with biopsy devices leading to product recalls, and the risk of infections related to biopsy procedures are expected to hinder the growth of this market to a certain extent.

The Asia Pacific region is the third-largest in terms of market share after North America and Europe. However, it is also the fastest-growing region in the world. Reforms introduced in India and China are poised to increase their purchasing power, further escalating the market's growth. China is the biggest name in this region, followed closely by Japan and India. Japan has a better healthcare infrastructure conducive to research, but India is the fastest-growing market due to the sheer size of the diseased population. 

One recent factor that may significantly shift the region's landscape is the anti-China sentiment in countries, especially India. With the Indian government's increased efforts to make everything in-house, the upcoming few years would be the one to watch out for as other countries’ dependence on China is likely to lessen, with India being an obvious alternative. South Korea and Australia are the other notable countries in the market.


Some of the notable companies dominating the global biopsy devices market profiled in this report are Medtronic, Leica Biosystems, Hologic Inc., Boston Scientific Corporation, Becton, Cook Medical Inc., C.R. Bard Inc., Mauna Kea Technologies, Ethicon EndoSurgery Inc., Veran Medical Technologies, Dickinson and Company, Fujifilm Medical Systems, MDxHealth, Argon Medical Devices Inc. and Intact Medical Corp.


  • In January 2021, Hologic Inc. acquired Somatex Medical Technologies GmbH. With this acquisition, Hologic increments its sales presence in Europe by enlarging its channel in Germany. Somatex focuses on developing and manufacturing minimally invasive surgeries in tumor diagnostics and a biopsy to continue its breast health portfolio growth. 
  • In February 2019, Medtronic retained the Synergy Cranial Software and StealthStation S7. The synergy cranial software and stealth station s7 surgical navigation system delivers complete 3dimensional images of the patient's brain, assisting the neurosurgeons in handling surgical tools and implants used during brain surgery. 
  • In July 2019, Fujifilm Medical Systems Inc. U.S.A extended its breast imaging solutions by introducing its Tomosynthesis Biopsy option for Aspire Cristalle mammography system. Tomosynthesis is to determine the 3-D coordinates of the suspicious lesion in the breast. 
  • In September 2018, Olympus won the FDA clearance for its EZ Shot 3-plus G, a single-use endoscopic ultrasound fine needle for fine needle aspiration and delicate needle biopsy procedures. The Shot 3plus used to perform methods on submucosal and extramural lesions over the GI tract. 

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample